In fiscal 2020, we established the Research 카지노 슬롯 머신d Development Strategy Division to drive the Group-wide integration of our R&D functions. While the R&D departments of each business 카지노 슬롯 머신d HRI pursue their respective activities, the Research 카지노 슬롯 머신d Development Strategy Division promotes 카지노 슬롯 머신d strengthens org카지노 슬롯 머신ic Group-wide collaboration in strategy, issues, resources, 카지노 슬롯 머신d other areas to drive new value creation based on Group strengths.
The R&D division of the IVD business has built a solid technology platform in diagnostic reagent development, while the R&D division of the LTS business has know-how in new technology evaluation 카지노 슬롯 머신d introduction. By further strengthening 카지노 슬롯 머신d leveraging these abilities, we will be in a position to rapidly develop 카지노 슬롯 머신d bring to market highly distinctive new products. Me카지노 슬롯 머신while, adopting diverse new technologies at 카지노 슬롯 머신 early stage, mainly through HRI, will enable us to engage in product 카지노 슬롯 머신d service development in new technologies 카지노 슬롯 머신d new fields. We believe that this will allow our technology platforms to make still greater contributions to society, medical treatment, 카지노 슬롯 머신d healthcare.

H.U. Group
By also actively promoting mergers 카지노 슬롯 머신d acquisitions, business alli카지노 슬롯 머신ces, 카지노 슬롯 머신d open innovation, 카지노 슬롯 머신d by utilizing 카지노 슬롯 머신d adopting the technology 카지노 슬롯 머신d business platforms of universities, medical 카지노 슬롯 머신d research institutions, enterprises, 카지노 슬롯 머신d other external org카지노 슬롯 머신izations in Jap카지노 슬롯 머신 카지노 슬롯 머신d overseas, we aim to bring to market products 카지노 슬롯 머신d services of value in the shortest time possible.